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Disease-relevant proteostasis regulation of cystic
fibrosis transmembrane conductance regulator
VR Villella1, S Esposito1, EM Bruscia1,2, M Vicinanza3, S Cenci4, S Guido5, M Pettoello-Mantovani6, R Carnuccio7,
MA De Matteis3, A Luini3,8, MC Maiuri7,9, V Raia*,10, G Kroemer*,9,11,12,13,14 and L Maiuri*,1,6
Mismanaged protein trafficking by the proteostasis network contributes to several conformational diseases, including cystic
fibrosis, the most frequent lethal inherited disease in Caucasians. Proteostasis regulators, as cystamine, enable the beneficial
action of cystic fibrosis transmembrane conductance regulator (CFTR) potentiators in DF508-CFTR airways beyond drug
washout. Here we tested the hypothesis that functional CFTR protein can sustain its own plasma membrane (PM) stability.
Depletion or inhibition of wild-type CFTR present in bronchial epithelial cells reduced the availability of the small GTPase Rab5
by causing Rab5 sequestration within the detergent-insoluble protein fraction together with its accumulation in aggresomes.
CFTR depletion decreased the recruitment of the Rab5 effector early endosome antigen 1 to endosomes, thus reducing the local
generation of phosphatidylinositol-3-phosphate. This diverts recycling of surface proteins, including transferrin receptor and
CFTR itself. Inhibiting CFTR function also resulted in its ubiquitination and interaction with SQSTM1/p62 at the PM, favoring its
disposal. Addition of cystamine prevented the recycling defect of CFTR by enhancing BECN1 expression and reducing SQSTM1
accumulation. Our results unravel an unexpected link between CFTR protein and function, the latter regulating the levels of CFTR
surface expression in a positive feed-forward loop, and highlight CFTR as a pivot of proteostasis in bronchial epithelial cells.
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Manipulating proteostasis by proteostasis regulators (PRs) has
emerged as a novel therapeutic approach for the treatment of
conformational diseases.1–5 Cystic fibrosis (CF) constitutes the
quintessential example of a conformational disease.6–8 CF is a
monogenic disease in which defective function of one single
protein, cystic fibrosis transmembrane conductance regulator
(CFTR), leads to major clinical manifestations, including
chronic lung inflammation with increased susceptibility to
respiratory bacterial infections, pancreatic dysfunction, raised
electrolyte levels in sweat and male infertility.9–11 CF is caused
by loss-of-function mutations of CFTR, a cAMP-regulated
chloride channel that is primarily located at the apical
membrane of epithelial cells.12,13 A single deletion, F508del,
occurs in about 70–90% of CF patients in Northern Europe and
North America.14 Due to its misfold, DF508-CFTR is prema-
turely degraded and loses its essential ion channel activity at
the plasma membrane (PM).9,15 DF508-CFTR can retain
channel activity if rescued at the PM by molecules that correct
its intracellular retention and degradation (correctors),16–20 as
well as by low temperature,21 but in this case DF508-CFTR is
rapidly dismissed from the PM and redirected from endosomal
recycling towards lysosomal degradation.22,23
We previously reported that defective CFTR function
induces reactive oxygen species (ROS)-dependent and
transglutaminase-2 (TGM2)-mediated sequestration of
BECN1, leading to defective autophagy and increased lung
inflammation.24 PRs such as cystamine or the superoxide
dismutase/catalase-mimetic EUK-13425,26 enable the bene-
ficial action of CFTR potentiators on DF508-CFTR mutant
tissues well beyond drug washout through restoring BECN1
expression and autophagy, thereby reducing the abundance
of SQSTM1/p62 (SQSTM1).24,27 This might suggest that,
once peripheral proteostasis has been re-established, PM-
resident DF508-CFTR could sustain its own PM stability.
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Based on these premises and incognita, we explored the
hypothesis that a functional CFTR might orchestrate periph-
eral proteostasis and ultimately regulate its own PM residence
and function.
Results
CFTR depletion reduces the availability of Rab5 and
impairs the recruitment of Rab5 effectors to early
endosomes (EEs). The abundance of the PM pool of surface
proteins/receptors that are internalized into endocytic vesicles
is determined by the balance between the rate of internaliza-
tion and the formation and budding of recycling tubules at
EEs, where the accuracy of receptor sorting is mediated by
the small GTPase Rab5 and its effectors early endosome
antigen 1 (EEA-1), type III phosphatidylinositol 3-kinase
(PtdIns3K, also known as hVps34, a protein that belongs to
the BECN1 interactome) and its product phosphatidylinositol
3-phosphate (PtdIns3P).28–31 Besides their effects on autop-
hagy, PtdIns3K and its product PtdIns3P regulate endosomal
fusion/maturation and trafficking.32–34 In addition, Rab5
participates to autophagosome formation through activating
hVps34, as part of the BECN1 macromolecular complex.31
We have reported that defective CFTR leads to functional
sequestration of BECN1 interactors, including hVps34, as the
result of TG2-mediated BECN1 crosslinking.24 Therefore,
we examined whether depleting CFTR from 16HBE14o-
bronchial epithelial cells would also affect endocytic function.
In control conditions (i.e. 16HBE14o- cells transfected with
scrambled siRNAs) the endosomal abundance of PtdIns3P,
which can be detected with a GFP-FYVE fusion protein,35–38
was strongly reduced after CFTR depletion (Figure 1a and
Supplementary Figures S1A and B). The TGM2 inhibitor
cystamine restored the endosomal localization of PtdIns3P to
the normal level unless it was combined with the PtdIns3K
inhibitor 3-methyl-adenine (3-MA) (Figure 1a).
CFTR depletion from 16HBE14o- cells lowered the cellular
levels of Rab5 protein (Figure 1b). Simultaneous treatment
with cystamine or transfection with HA-tagged BECN1 (HA-
BECN1)24,27 abolished the reduction of Rab5 protein levels
induced by CFTR depletion (Figure 1b). Depletion of BECN1,
VPS34 (vacuolar protein sorting 34) or VPS15 (but not
that of the autophagy-related gene product ATG14)39,40
abrogated the capacity of cystamine to restore Rab5
expression (Figure 1c; Supplementary Figure S1C), indicating
that these cystamine effects required a functional BECN1/
hVps34/hVps15 complex.
We previously reported that defective CFTR leads to
accumulation of the BECN1 interactome in the detergent-
insoluble protein fraction and its sequestration within intracel-
lular aggregates as the result of autophagy inhibition with
accumulation of SQSTM1 and proteasome overload.24 Here
we show that CFTR depletion from 16HBE14o- cells resulted
in the accumulation of Rab5 in the detergent-insoluble protein
fraction, a phenomenon that was enhanced by the incuba-
tion with the proteasomal inhibitor MG132 (Figure 2a;
Supplementary Figures S2A and B). Moreover, CFTR
depletion resulted in Rab5 sequestration within HDAC6þ
aggresomes (Figure 2b). These features were reversed by
transfection with HA-BECN1 or addition of cystamine unless
the latter treatment was combined with hVps34 depletion
(Figure 2a). Similarly to Rab5, Rab7 protein levels were
significantly decreased in CFTR-depleted 16HBE14o- cells
(Figure 1b) and were restored by transfection with HA-BECN1
or cystamine, unless BECN1, VPS34 or VPS15 (but not
ATG14) were depleted by siRNAs (Figure 1c). However,
in contrast to Rab5, Rab7 did not redistribute into
the insoluble protein fraction, following CFTR depletion
(Figure 2a; Supplementary Figure S2B), suggesting subtle
differences in the mechanisms causing the inactivation of
Rab5 and Rab7.
The expression of SQSTM1 is well known to increase in
conditions of autophagy impairment, because this protein is an
autophagic substrate, and then favors aggresome forma-
tion.41–43 SQSTM1 also accumulates in 16HBE14o- cells upon
CFTR depletion as the result of disabled autophagy.24 Here
we demonstrate that in CFTR-depleted 16HBE14o- cells, Rab5
co-localized with SQSTM1 in intracellular aggregates
(Figure 2c) and siRNA-mediated depletion of SQSTM1,
together with that of CFTR, prevented both the sequestration
of Rab5 in the insoluble protein fraction (Figure 2a) and the
reduction of Rab5 and Rab7 protein levels (Figure 1b).
These results support the intimate connection between
autophagy and endosomal trafficking.31,32 They also indicate
that CFTR depletion causes reduced Rab5 availability and
likely perturbs endosomal function.
CFTR depletion impairs endosomal trafficking of surface
receptors in bronchial epithelial cells. We examined the
effects of CFTR depletion on the endocytic trafficking of two
surface receptors: (i) the transferrin receptor (TfR), which
recycles from the early/recycling endosomes to the PM44 and
(ii) the epidermal growth factor receptor (EGFR), which is
sorted from the early endosomes towards degradative
compartments (late endosomes (LEs)/lysosomes) following
EGF-induced internalization.45–47 As compared with
scrambled siRNA-treated cells, CFTR-depleted 16HBE14o-
cells exhibited reduced PM binding of Tf at 4 1C (Figure 3a),
along with reduced cellular uptake of Tf (Figures 3b and c).
This reduced uptake was due to impaired exposure of TfR to
the cell surface rather than due to a defect in the
internalization process per se (Figure 3d). Importantly, the
recycling rates of internalized Tf were reduced by CFTR
depletion (Figure 3e), in line with the observation that, after
CFTR depletion, fluorescent-labelled Tf did not localize at
Rab11þ endosomes for up to 15 min after chase with
unlabeled Tf, as this was the case in control conditions
(Supplementary Figure S3A). Surface biotinylation and mem-
brane fractionation confirmed the reduced exposure of TfR at
the cell surface following CFTR depletion (Supplementary
Figure S3B). The effects of CFTR depletion on TfR binding and
recycling were abrogated by the enforced expression of HA-
BECN1 (Figure 3e), as well as by cystamine, unless 3-MA was
added (Figure 3e; Supplementary Figures S3A and B).
To unravel whether the effects of CFTR depletion rely on
the loss of CFTR function, we used the pharmacological
CFTR inhibitor CFTRinh-172. In spite of the fact that short-time
CFTR-unrelated effects of CFTRinh-172 have been described
in CFTR lacking HeLa cells,48 a long-term (24–48 h) treatment
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with CFTRinh-172 led to CFTR-specific effects.
49,50
CFTRinh-172 recapitulated the effects of CFTR depletion
as it increased ROS-mediated TGM-2 SUMOylation and
SQSTM1 levels only in 16HBE14o- but not in HeLa cells
(Supplementary Figures S4A–C). In addition, CFTRinh-172 was
effective in favoring Rab5 sequestration within the insoluble
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Figure 1 CFTR depletion reduces the availability of Rab5 and the recruitment of Rab5 effector EGFP-tagged-FYVESARA to early endosomes. (a) Confocal microscopic
images of 16HBE14o- cells transfected with a plasmid encoding EGFP-tagged-FYVESARA and with CFTR-specific or scrambled siRNA (50 nM) in the presence or absence of
cystamine (250mM) with/without 3-MA (3 mM). Left, confocal microscopic images of EEA1 and EGFP-tagged-FYVESARA. Insets: boxed area show merged images of EGFP-
tagged-FYVESARA (green) and EEA1 (red). Scale bar, 10 mm. Right, number of FYVESARA spots per cell were counted using AnalySIS software. Means±S.D. (n¼ 30 cells
per experiment; analysis of three independent experiments). *Po0.05 compared with scrambled siRNA-treated cells. In this analysis, the total fluorescence intensity per cell
was used to monitor EGFP-tagged-FYVE transfection efficiency and was calculated for each sample using Zeiss LSM 510 software (version 3.2). (b) Effects of CFTR depletion
on Rab5 and Rab7 protein levels. Effects of cystamine (250mM), HA-Beclin-1 overexpression or SQSTM1 siRNA (50 nM) in CFTR depleted 16HBE14o- cells. Left, Rab5 and
Rab7 protein expression versus whole cell lysates. b-actin expression was measured as a loading control. Right, densitometric analysis of protein levels expressed as
percentage of control. Mean±S.D., *Po0.05 compared with untreated cells, #Po0.01 versus CFTR siRNA (analysis of variance (ANOVA)). (c) The cells were treated with or
without CFTR siRNA (50 nM) in the presence or absence of cystamine (250mM), after transfection with the indicated siRNAs (50 nM each). Left, expression of Rab5 and Rab7
in 16HBE14o- cells. Right, densitometric analysis of protein levels expressed as percentage of control. Mean±S.D., *Po0.05, compared with untreated cells, #Po0.01
compared with cystamine-treated cells (ANOVA)
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protein fraction (Supplementary Figures S4D and E) as well as
in impairing recycling of TfR in primary human bronchial
epithelial cells (Figure 3f), thus recapitulating the effects of
CFTR depletion from16HBE14o- cells.
We also investigated the effects of CFTR depletion on
EGF-induced trafficking of the EGFR. In 16HBE14o- cells
transfected with scrambled siRNAs, EGF (and its receptor)
was efficiently degraded after 30 and 60 min of stimulation. By
contrast, CFTR depletion delayed the EGFR degradation in
16HBE14o- cells, and EGFR was still retained up to
60 min following internalization (Figures 4a and b). HA-
BECN1 and cystamine neutralized these effects of CFTR
depletion on EGFR degradation in a 3-MA-inhibitable fashion
(Figures 4a and b).
Perturbed endosomal trafficking of TfR and EGFR was also
observed in parental CFBE41o- cells, which lack a functional
CFTR due to the homozygous DF508-CFTR mutation
(Supplementary Figures S5A and B). Furthermore, Rab5
protein levels were significantly reduced in CFBE41o- cells, as
Rab5 accumulated in the insoluble protein fraction even
in the absence of incubation with the proteasomal inhibitor
MG132 (Supplementary Figures S6A and B), in line with
the observation that CF epithelial cells show SQSTM1
accumulation and proteasome overload as the result of the
autophagy inhibition.24
Low Rab7 protein levels were detected in CFBE41o- cells,
although Rab7 was not recovered from the detergent-
insoluble protein fraction (Supplementary Figures S6A and
B), suggesting impaired Rab5-Rab7 transition. Indeed, the
Rab network also involves other components of the
BECN1 interactome, such as UV-irradiation-resistance-asso-
ciated gene (UVRAG) that interacts with the HOPS
complex at the EEs, thus recruiting and activating Rab7 and
favoring the Rab5 to Rab7 transition.32,51 Decreased
UVRAG impairs endosomal fusion and delays the endocytic
trafficking and degradation of EGFR.32,51 We found that in
CFBE41o- cells UVRAG was sequestered within the
detergent-insoluble protein fraction (Supplementary Figure
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Figure 2 Effects of CFTR depletion on Rab5 distribution after proteasome inhibition in bronchial epithelial cells. (a–c) 16HBE14o- cells were treated with the proteasome
inhibitor MG132 (50 mM). (a) The cells were treated with or without CFTR siRNA (50 nM) in the presence or absence of cystamine (250 mM) after transfection with the indicated
siRNAs (50 nM each) or transfected with CFTR siRNA (50 nM) together with SQSTM1 siRNA (50 nM). Left, immunoblots of Rab5 and Rab7 in the detergent-insoluble
fractions. Right, densitometric analysis of protein levels expressed as fold increase. Mean±S.D., *Po0.05 compared with scrambled siRNA-treated cells, #Po0.01
compared with cystamine-treated cells, (analysis of variance). (b and c) Effects of HA-Beclin-1 overexpression or cystamine (250mM) in CFTR depleted 16HBE14o- cells.
Cells were co-stained for Rab5 and HDAC6 (b) or with Rab5 and SQSTM1 (c). Upper, confocal microscopic images, bottom, quantitative measurement of co-localizations.
Mean±S.D. of five independent experiments (n¼ 50 cells for each experiment). *Po0.05 compared with scrambled siRNA-treated cells. Bar¼ 10mm
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Figure 3 CFTR depletion impairs TfR recycling in bronchial epithelial cells. (a–d) 16HBE14o- cells were transfected with either 50 nM human CFTR siRNA or scrambled
oligonucleotides. (a) The cells were exposed to Alexa-Fluor-488-Tf for 1 h at 4 1C (panel). Insets: enlargement of the boxed area, with images of Tf (green). (b) Then, the cells
were warmed to 37 1C in complete medium for 5 min. Bar¼ 10mm. (c) Quantification of cell-associated A488-Tf, evaluated as mean fluorescence intensities per cell at the
indicated times, referred to the untreated samples and expressed as indicated (a.u., arbitrary units). Data are mean values±S.D. (n¼ 30 cells; three independent
experiments). *Po0.05 compared with scrambled siRNA-treated cells, (analysis of variance (ANOVA)). (d) The PM exposure of Tf (Bound Al488-Tf) and its internalization
(internalized Al488-Tf) were measured through binding at 4 1C and internalization at 37 1C for 5, 15, 30 and 60 min. The fluorescence intensities were quantified and expressed
as percentages of bound Tf. Data are mean values±S.D. (n¼ 30 cells; three independent experiments). *Po0.05 compared with scrambled siRNA-treated cells (ANOVA).
(e) 16HBE14o- cells were transfected with either 50 nM human CFTR siRNA or scrambled oligonucleotides in the presence of either HA-tagged BECN1 or the empty vector or
cultured with cystamine (250mM) followed by 3-MA (3 mM). For analysis of Tf recycling, the cells were loaded with Alexa-Fluor-488-Tf for 1 h at 37 1C (Load) and chased in
complete medium for 30 and 60 min (Chase). The fluorescence intensities remaining in the cells after 30 and 60 min of chase were quantified and expressed as percentages of
loaded Tf. Data are mean values± S.D. (n¼ 30 cells; three independent experiments). *Po0.05 compared with scrambled siRNA-treated cells, #Po0.01 compared with
cystamine treated cells (ANOVA). (f) Normal human primary bronchial epithelial cells were cultured in the presence of CFTRinh172. For Tf recycling, the cells were loaded with
Alexa-Fluor-488-Tf for 1 h at 37 1C (Load) and chased in complete medium for 30 and 60 min (Chase). The fluorescence intensities remaining in the cells after 30 and 60 min of
chase were quantified and expressed as percentages of loaded Tf. Data are mean values±S.D. (n¼ 30 cells; three independent experiments). *Po0.05 compared with
scrambled siRNA-treated cells (ANOVA)
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Figure 4 CFTR depletion delays EGFR endosomal trafficking in bronchial epithelial cells. (a and b) 16HBE14o- cells were transfected with either 50 nM human CFTR
siRNA or scrambled oligonucleotides in the presence of either HA-BECN 1 or the empty vector or cultured with cystamine (250mM) with/without 3-MA (3 mM). (a) Upper, the
cells were serum starved for 12 h at 37 1C and then incubated for 1 h at 4 1C with 100 ng/ml EGF–AlexaFluor-488. The uptake of EGF and its movement along the endocytic
pathway were followed by incubating the cells at 37 1C for the indicated times. Bar¼ 10mm. Bottom, quantification of cell-associated A488-EGF, evaluated as mean
fluorescence intensities per cell at the indicated times, and expressed as indicated (a.u., arbitrary units). Data are mean values±S.D. (n¼ 30 cells; three independent
experiments). *Po0.05 compared with scrambled siRNA-treated cells, #Po0.01 compared with cystamine-treated cells (analysis of variance). (b) The cells were stimulated
with EGF (100 ng/ml) for 60 min, fixed, permeabilized and labelled with antibodies against the EGFR. Bar¼ 10mm. Bottom, quantification of cell-associated EGFR, evaluated
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with scrambled siRNA-treated cells
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S6C) and accumulated in HDAC6þ aggregates (Supple-
mentary Figure S6D). Cystamine effectively restored
the soluble fraction of UVRAG protein (Supplementary
Figure S6C).
Altogether, these results indicate that a functional CFTR is
required for optimal endosomal trafficking of surface recep-
tors in respiratory epithelial cells, thus regulating the
abundance of the PM pool of surface proteins.
Functional inhibition of CFTR induces ubiquitination of
CFTR protein and its interaction with SQSTM1 at the
PM. We examined whether the function of CFTR would
regulate the recycling of CFTR protein and hence its own PM
stability. The abundance of CFTR at the PM is mainly
determined by its recycling through the Rab11þ endocytic
pathway.52,53 It has been reported that ubiquitylated CFTR
becomes unstable at the PM and is diverted to lysosomal
degradation.54 Moreover, SQSTM1 can also function as a
critical regulator of internalization, trafficking and sorting of
ubiquitinylated surface proteins.55,56 As SQSTM1 protein
levels increase after functional CFTR depletion in
16HBE14o- cells (Supplementary Figure S4C), we wondered
whether the functional CFTR inhibition might trigger the
ubiquitination of CFTR at the PM, increase PM levels of
SQSTM1 and hence stimulate CFTR/SQSTM1 interaction.
To this aim, we incubated 16HBE14o- cells with CFTRinh-172
to analyze CFTR by means of anti-CFTR Abs. Addition of
CFTRinh-172 to 16HBE14o- cells increased the PM abundance
of both SQSTM1 and the ubiquitin ligase carboxyl-terminus
heat shock cognate 70 (Hsc70)–interacting protein (CHIP), a
major player of PM protein quality control in CF22 (Figure 5a).
CFTRinh-172 caused a dramatic increase in CFTR ubiquitination
(which was barely detected in untreated 16HBE14o- cells)
and enhanced the interaction between PM-resident CFTR
and SQSTM1, as determined by co-immunoprecipitation
(Figure 5b).
Moreover, after CFTR inhibition, both CFTR and SQSTM1
were detected within EEs, as revealed by subcellular
fractionation followed by immunoblotting (Figure 5c). Accord-
ingly, internalized CFTR co-localized with SQSTM1 at the
epithelial surface as well as within enlarged vesicles in primary
human bronchial epithelial cells treated with CFTRinh-172
(Supplementary Figures S7A and B). Cystamine neutralized
the effects of CFTRinh-172 as it prevented PM ubiquitination of
CFTR, SQSTM1 accumulation both at PM and in the
endosomal compartment, as well as SQSTM1/CFTR interac-
tion in bronchial epithelial cells (Figures 5a–c and
Supplementary Figures S7A and B), unless 3-MA was added
to the system (Supplementary Figure S7A). Next, we
investigated whether the accumulation of SQSTM1 at EEs
following CFTR inhibition could favor Rab5 sequestration. To
this aim, we overexpressed either wild-type (wt)-SQSTM1 or a
SQSTM1 mutant lacking the ubiquitin-binding domain (delta-
UBA mutant) in 16HBE14o- cells in the presence or absence
of CFTRinh-172. The overexpression of wt-SQSTM1, but not
that of delta-UBA SQSTM1, recapitulated the effects of CFTR
inhibition in causing the redistribution of Rab5 into the
detergent-insoluble protein fraction (Figures 5d and e).
Moreover, the enforced expression of delta-UBA SQSTM1,
but not that of wt-SQSTM1, abrogated these effects of CFTR
inhibition (Figures 5d and e). These data indicate that the
ubiquitin-binding activity of SQSTM1 is pivotal for inducing
Rab5 sequestration within the detergent-insoluble protein
fraction upon CFTR inhibition.
To determine whether functional inhibition of CFTR would
lower its own recycling, we developed an assay in which
16HBE14o- cells were either left untreated or were pretreated
with CFTRinh-172 for 24 h, and cycloheximide (CHX) was added
during the last 4 h of incubation to inhibit protein neosynth-
esis.22,27 16HBE14o- cells were then shifted to 4 1C for 1 h,
followed by incubation at 37 1C to induce internalization of PM-
resident endogenous CFTR. In contrast to untreated cells,
CFTRinh-172-treated cells manifested negligible CFTR localiza-
tion in Rab11þ endosomes 30 min after internalization
(Figure 6a). The deranged recycling of CFTR following
functional CFTR inhibition was reversed by cystamine unless
BECN1 was depleted during cystamine treatment (Figure 6a).
Moreover, in CFTRinh-172-treated cells, CFTR was detected
within LAMP1þ vesicles as late as 90 min following internaliza-
tion, unless SQSTM1 was depleted by siRNA (Figure 6b).
Thus, functional inhibition of CFTR perturbs CFTR recycling as
it diverts CFTR towards lysosomal degradation.
Altogether, these results indicate that the inhibition of CFTR
function in bronchial epithelial cells enhances the function and
abundance of SQSTM1 at the PM, thus favoring PM disposal
of ubiquitylated CFTR and perturbing the endosomal routes
that mediate CFTR recycling.
CFTR function controls CFTR protein stability at the PM
of bronchial epithelial cells. The aforementioned data
suggest that the function of CFTR may determine the stability
of CFTR protein at the PM. To further explore this possibility,
16HBE14o- cells were incubated with CFTRinh-172 for 24 h in
the presence or absence of EUK-134 or cystamine with/
without 3-MA, with CHX (100 mg/ml), which was added twice
at 8 and 4 h before termination of the experiment.27 CHX
toxicity in the system was excluded by a 3-[4,5-dimethylthia-
zol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) cell viability
assay (Supplementary Figures S8A and B). Then the
abundance of CFTR at the PM was determined by cell-
surface biotinylation, purification of biotinylated proteins and
immunoblotting. CFTRinh-172 reduced the overall abundance of
PM-resident mature glycosylated CFTR (band C) by more
than two-thirds (27% of remaining band C versus 91% in cells
treated with CHX alone, considering 100% the value of
untreated cells) (Figure 7a), and this effect was fully reversed
by simultaneous addition of either cystamine or EUK-134 (88
and 85% of the remaining band C, respectively) unless 3-MA
was added to the system or BECN1 was depleted by siRNAs
(Figure 7a). Depletion of SQSTM1 also abrogated the capacity
of CFTRinh-172 to reduce the PM abundance of CFTR
(Figure 7a). Finally, CFTRinh-172 lowered the PM abundance
of CFTR in a cystamine-inhibitable fashion, in primary human
bronchial epithelial cells (Figure 7b), confirming the tight link
between CFTR function and CFTR stability.
CFTR sufficiency is required for PM stability of the
misfolded DF508-CFTR mutant. We previously reported
that DF508-CFTR mutant protein, which has been rescued at
the epithelial surface of DF508-CFTR homozygous epithelial
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Figure 5 Functional inhibition of CFTR leads to ubiquitination of CFTR at the PM of bronchial epithelial cells together with interaction with SQSTM1. (a and b)
16HBE14o- cells were treated with CFTRinh172 (20mM) with/without cystamine (250mM) in the presence of CHX during the last 8 h of incubation. The incubation for 4 h at 4 1C
was used to block endocytosis. (a) Left, expression of CHIP, SQSTM1 and Ubiquitin (Ab, P4D1) from membrane fraction. E-Cadherin, LAMP1, EEA1, Rab7 and b-actin were
used as control of the membrane cell-surface protein fractionation. Right, densitometric analysis of protein levels expressed as fold increase. Mean±S.D., *Po0.05
compared with untreated cells, #Po0.01 versus CFTRinh172-treated (analysis of variance (ANOVA)). (b) Protein samples from the PM were immunoprecipitated with anti-
CFTR (clone CF3) and immunoblotted with anti-CFTR (clone M3A7), anti-SQSTM1 or anti-Ubiquitin (P4D1) Abs. Immunoprecipitation was performed with 500mg of protein
samples. Right, densitometric analysis shows the abundance of ubiquitylated CFTR adducts normalized for the expression level of their band C and expressed as fold increase
relative to that of untreated cells (means±S.D. of three experiments). *Po0.05 compared with untreated cells, #Po0.01 versus CFTRinh172-treated (ANOVA). (c)
16HBE14o- cells were treated with CFTRinh172 in the presence or absence of cystamine. After 15 min following internalization, early endosome fraction was purified by
sucrose cushion and immunoblotted for the early endosome marker EEA1. The absence of the late endosome marker Rab7 or lysosome marker LAMP-1 or membrane marker
E-Cadherin confirms fraction-specific labeling. Left, representative immunoblot analysis of CFTR (clone 3MA7) and SQSTM1 in EEA1 positive fraction. Right, densitometric
analysis of protein levels expressed as fold increase. Mean±S.D., *Po0.05 compared with untreated cells, #Po0.01 versus CFTRinh172-treated (ANOVA).
(d and e) 16HBE14o- cells were transfected with Flag-SQSTM1-wt or Flag-SQSTM1-deltaUBA with or without CFTRinh-172. (d) Upper, immunoblots of Rab5 in whole cell
lysates. Flag was used as control of transfection. b-actin expression was measured as a loading control. Bottom, densitometric analysis of protein levels expressed as fold
increase. Mean±S.D., *Po0.05 compared with untreated cells (ANOVA). (e) The cells were treated with the proteasome inhibitor MG132 (50 mM). Upper, immunoblots
of Rab5 in the detergent-insoluble fractions. Bottom, densitometric analysis of protein levels expressed as fold increase. Mean±S.D., *Po0.05 compared with untreated cells
(ANOVA)
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Figure 6 Functional inhibition of CFTR impairs CFTR recycling in bronchial epithelial cells. (a) 16HBE14o- cells were treated with CFTRinh172 (20mM) and/or 50 nM of
scrambled or SQSTM1 siRNAs or cystamine in the presence or absence of BECN1 siRNAs. CHX (100mg/ml) was added during the last 4 h. The cells were then shifted at 4 1C
for 1 h and then at 37 1C up to 30 min to allow internalization. Upper, confocal microscopic images of CFTR co-stained with Rab11, 30 min after internalization. Bottom,
quantitative measurement of co-localization. Mean±S.D. of five independent experiments (n¼ 50 cells for each experiment). *Po0.05 compared with untreated cells.
Bar¼ 10mm. (b) 16HBE14o- cells were treated with CFTRinh172 (20mM) and 50 nM of scrambled or SQSTM1 siRNAs. Upper, confocal microscopic images of CFTR (clone
CF3) co-stained with LAMP1, 90 min after internalization. Bottom, quantitative measurement of co-localization. Mean±S.D. of three independent experiments (n¼ 50 cells
for each experiment). Representative of three different experiments. *Po0.05 compared with untreated cells. Bar¼ 10mm
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cells by cystamine treatment, can reside at the PM well
beyond cystamine washout. This suggests that DF508-CFTR
might sustain its own PM stability. To address this issue, we
tested whether a CFTR-sufficient context (i.e., untreated
16HBE14o- cells) could also generate a permissive environ-
ment for PM stability of the misfolded DF508-CFTR
mutant.22,27 We transfected 16HBE14o- cells with HA-
tagged DF508-CFTR at 37 1C, an experimental condition
that does not allow DF508-CFTR to traffic to the PM in cells
that lack wt-CFTR expression.3,4,6 Mature DF508-CFTR
band C was detected in immunoblots of whole 16HBE14o-
cell lysates with an anti-HA Ab (Supplementary Figure S9A).
Twenty-four hours post transfection, the cells were cultured
for 8 h in the presence of CHX (100 mg/ml, refreshed every
4 h) to inhibit protein neosynthesis, as described above.
Immunoblotting of surface biotinylated proteins revealed
that DF508-CFTR band C was stably expressed at the
PM of 16HBE14o- even after 8 h following CXH treatment
Blot:
CFTR band C
E-cadherin
250
130
36
kDa
+CFTR inh172
SQ
ST
M
1
 
si
R
N
A
Sc
ra
m
bl
ed
BE
CN
1 
si
R
N
A
+ Cystamine
3-
M
A
+8 h, CHX
EU
K-
13
4Surface
biotinylated proteins
0
Ex
pr
es
sio
n 
%
o
f b
an
d 
C 
at
 P
M
**
3-
M
A
+8h, CHX
+Cystamine
Sc
ra
m
bl
ed
SQ
ST
M
1
si
R
N
A
 
EU
K-
13
4
*
β-actin
Cy
st
am
in
e
CFTR inh172
Blot:
E-cadherin
Surface
biotinylated proteins
250
130
36
kDa
CFTR band C
+8 h, CHX
0
Cy
st
am
in
e
+8h, CHX
*
#
Ex
pr
es
sio
n 
%
 o
f
 
 
ba
nd
 C
 a
t P
M
#
+CFTR inh172
Primary bronchial
epithelial cells 
+CFTR inh172
β-actin
BE
CN
1 
si
R
N
A
100
75
25
50
100
75
50
25
Figure 7 CFTR function controls CFTR protein stability at the PM of bronchial epithelial cells. (a) 16HBE14o- cells were incubated with/without CFTRinh172 in the presence
or absence of EUK-134 or cystamine with or without 3-MA or BECN1 siRNAs. CFTRinh172-treated cells were alternatively transfected with SQSTM1 siRNAs. CHX (100mg/ml)
was added during the last 8 h of incubation. Left, Surface-biotinylated proteins from the PM and immunoblot with anti-CFTR Ab (clone M3A7). Right, densitometric
measurement of the residual wt-CFTR band C at PM expressed as percentage of initial amount normalized to E-cadherin levels. Mean±S.D. of triplicates of three different
experiments; *Po0.05, #Po0.01 compared with initial amount with CHX (analysis of variance (ANOVA)). (b) Normal human primary bronchial epithelial cells were treated
with/without CFTRinh172 in the presence or absence of cystamine. CHX (100mg/ml) was added during the last 8 h of incubation. Left, surface-biotinylated proteins from the PM
and immunoblot with anti-CFTR Abs (clone 3MA7). Right, densitometric measurement of the residual wt-CFTR band C at PM expressed as the percentage of initial amount
normalized to E-cadherin levels. Mean±S.D. of triplicates of three different experiments; *Po0.05 compared with untreated cell, #Po0.01 versus CFTRinh172-treated cells
(ANOVA)
Figure 8 CFTR function is required for PM stability of DF508-CFTR in bronchial epithelial cells. (a) 16HBE14o- cells were transfected with HA-DF508-CFTR and then
incubated with/without CFTRinh-172 in the presence or absence of cystamine with/without 3-MA. CHX (100mg/ml) was added during the last 8 h of incubation. Left, surface-
biotinylated proteins from the PM were immunoblotted with anti-HA Ab. Right, densitometric analysis of the residual band C at PM expressed as the percentage of initial
amount normalized to E-cadherin levels. Mean± S.D. of triplicates of three different experiments; *Po0.05 compared with untreated cells, #Po0.01 versus cystamine-
treated cells (analysis of variance (ANOVA)). (b) 16HBE14o- were transfected with HA-DF508-CFTR and/or with scrambled or SQSTM1 siRNAs (50nM) and then incubated
with CFTRinh172 for 24 h. CHX was added during the last 8 h. Left, surface-biotinylated proteins from the PM of the transfected CFTR band C by anti-HA Abs. Right,
densitometric analysis the residual band C at PM expressed as the percentage of initial amount normalized to E-cadherin levels. Mean±S.D. of triplicates of three different
experiments; *Po0.05 compared with untreated cells, #Po0.01 versus scrambled treated cells incubated with CFTRinh172 (ANOVA). (c) Schematic representation of the
results. (1) CFTR inhibition leads to the sequestration of the BECN1 interactome as the result of TG2-mediated BECN1 crosslinking that reduces the availability of PtdIns3K
(Vps34). This results in autophagy inhibition with accumulation of SQSTM1 (p62) leading to proteasome overload and accumulation of ubiquitin. The inhibition of CFTR
function induces CFTR ubiquitination at the PM and favors the interaction between CFTR and p62. (2) The reduced PtdIns3K availability also decreases PtdIns3P at the early
endosomes and reduces Rab5 protein levels, thus impairing endosomal function. The binding of p62 to ubiquitylated CFTR at the PM diverts CFTR recycling and targets CFTR
to degradation. Moreover, p62 present at early endosomes favors Rab5 sequestration within insoluble protein aggregates and delays the progression of internalized CFTR
though the degradative route, thus causing its local accumulation
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(Figure 8a). However, pretreatment with CFTRinh-172 strongly
reduced the abundance of PM DF508-CFTR in this
experimental setting, unless cystamine (but not cystamine
combined with 3-MA) was added as well (Figure 8a). Direct
depletion of SQSTM1 by siRNAs mimicked the effects of
cystamine (Figure 8b). Cystamine did not influence the PM
abundance of DF508-CFTR rescued by low temperature in
CFTR-lacking HeLa cells54,57 (Supplementary Figure S10A),
indicating that cystamine does not directly target DF508-
CFTR and rather corrects the derangement of peripheral
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proteostasis resulting from CFTR inhibition in bronchial
epithelial cells. These results indicate that a CFTR-sufficient
context generates permissive conditions for DF508-CFTR
mutant to reside at the PM of airway epithelial cells.
Discussion
The proteostasis network is a homeostatic system that
responds to multiple perturbations, be they genetically deter-
mined or acquired due to environmental stress or aging. The
accumulation of misfolded proteins secondary to destabilizing
genetic mutations or the aging-related decline of proteostasis
contributes to several human conformational diseases, includ-
ing neurodegenerative disorders, type II diabetes and CF.1–5
This study indicates that CFTR is a key player of the
proteostasis network of bronchial epithelial cells. Our results
provide evidence in favor of the hypothesis that functional
perturbation of CFTR affects endosomal trafficking of cell-
surface proteins exemplified by TfR, EGFR and CFTR itself.
This results from the functional sequestration of BECN1,
which has two negative effects on intracellular trafficking
related to CFTR.24 First, CFTR depletion or inhibition reduces
the local generation of PtdIns3P, which is pivotal in regulating
endosomal fusion/maturation and trafficking,28–32 by inducing
functional sequestration of the BECN1-interactor hVps34.
Second, CFTR depletion or inhibition and consequent BECN1
inactivation disables autophagy, thereby enhancing the
abundance of SQSTM1 both at the EEs (thus favoring
sequestration of Rab5 in the detergent-insoluble protein
fraction and favoring its aggregation) and at the PM (thus
targeting ubiquitinylated CFTR to degradation). SQSTM1 is
an ubiquitin-binding protein that accumulates in conditions of
defective autophagy, leading to proteasome overload and
favoring aggresome formation.42,43,58 Interestingly, direct
depletion of SQSTM1 increases BECN1 protein levels
(through reducing TGM-2 levels)24 and recapitulates the
effects of either genetic (by enforced expression) or pharma-
cological (by cystamine) rescue of BECN1 as it can restore
DF508-CFTR at the epithelial surface and blunt lung
inflammation in CF mice.27 Here, we show that SQSTM1
depletion avoids the deleterious effects of the functional
CFTR inhibition on PM abundance and recycling of CFTR
protein. By contrast, enforced expression of SQSTM1, but not
that of the delta-UBA SQSTM1 mutant, recapitulated the
effects of CFTR inhibition on Rab5 sequestration. These
results highlight SQSTM1 as a pivot of CFTR-mediated
regulation of peripheral proteostasis (Figure 8c).
Altogether our data indicate that pharmacological or genetic
inhibition of CFTR ignites the disposal of PM-resident CFTR.
This may have important implications for CF, as it may initiate a
CF-relevant vicious cycle in which the loss of CFTR function
negatively impacts on the overall abundance of the protein
within the PM, hence further reducing the function of
CFTR. Such a scenario may explain how it is sufficient to
temporarily interrupt this negative feed-forward loop, for
instance, by transient treatment with cystamine, to obtain a
long-lasting therapeutic effect that improves signs of lung
inflammation in DF508-CFTR homozygous mice.27 Indeed,
re-establishing and sustaining a functional CFTR at the PM of
bronchial epithelial cells generates permissive conditions
for misfolded DF508-CFTR to traffic to and reside at the PM
of bronchial epithelial cells.27
Conformational diseases are characterized by the prema-
ture degradation of unstable proteins or, on the contrary, their
unwarranted and harmful accumulation in intra- or extracellular
compartments. The common view is that such diseases are
caused by mutations that directly affect the structure of the
protein, resulting in abnormal proteostasis due to excessive or
deficient proteolysis. To our knowledge, CFTR constitutes the
first example of a disease-relevant protein that must be fully
functional to avoid its premature degradation, hence unveiling
an unexpected connection between protein function and
proteostasis. The proteostasis network is probably unique to
each cell type and tissue.1,4,5 Indeed, many conformational
diseases manifest as tissue-specific disorders, in spite of the
fact that mutant proteins are expressed near-to-ubiquitously in
many different tissues. Understanding whether other disease-
relevant proteins might orchestrate proteostasis in their
specific context could unveil new strategies for drug discovery
in other conformational diseases.
Materials and Methods
Cell lines and treatments. Normal 16HBE14o- or CFTR-mutated
CFBE41o- bronchial epithelial cells (kindly provided by D.C. Gruenert) were
cultured with minimum essential medium (MEM) Earl’s salt (200 mM L-Glutamine,
10% FBS and the appropriate amount of penicillin/streptomycin). Human, normal
primary bronchial/tracheal epithelial cells or HeLa adenocarcinoma cell lines (LGC
Promochem, Milan, Italy) were cultured as recommended by the American Type
Culture Collection.
16HBE14o- cells were transfected with GFP-tagged FYVE domain of SARA
(PtdIns3P probe, GFP-FYVE)46 and then with CFTR-specific or scrambled siRNAs
or incubated with CFTRinh-172 for 24 h (20mM, refreshed every 4 h, Calbiochem,
Darmstadt, Germany) in the presence or absence of cystamine (250mM, Sigma-
Aldrich, St Louis, MO, USA) or EUK-134 (50mg/ml, Vinci-biochem, Florence, Italy)
or HA-BECN1 overexpression24 or scrambled or SQSTM1 siRNA. The cells were
also treated with CFTR siRNA or CFTRinh172 and incubated with cystamine in
presence of BECN1, hVps34, hVps15 or ATG14 siRNAs or with cystamine with/
without 3-MA (3 mM, Sigma-Aldrich). In another set of experiments, the cells were
previously transfected with Flag-SQSTM1-wt or Flag-SQSTM1-DUBA(E396X) with
or without CFTRinh-172. The cells were also incubated with CHX (100mg/ml,
refreshed every 4 h, Sigma-Aldrich)22,55 or with MG132 (50mM for 6 h, Calbiochem)
where indicated. CHX toxicity was excluded by a MTT cell viability assay, as previously
described.27 In other experiments, the cells were incubated at 4 1C for 1 h to block
endocytosis and then shifted at 37 1C to allow CFTR internalization. In another set of
experiments, the cells were previously transfected with HA-tagged-DF508-CFTR and
then treated with CFTRinh-172 with/without cystamine followed by 3-MA.
Human primary epithelial cells were incubated without/with CFTRinh-172 in the
presence or absence of cystamine.
CFBE41o- cells were transfected with HA-BECN1 or incubated with cystamine
(250mM, Sigma-Aldrich).24,27
HeLa cells were transfected with HA-tagged-DF508-CFTR and then incubated at
26 1C for 30 h with/without cystamine. CHX was added during the last 8 h.
Plasmids. The pcDNA3-HA-BECN 1 (gift from N. Mizushima), pcDNA3.
1HA-DF508-CFTR (PRIMM), pCMV-Tag2bFLAG-SQSTM1 wt or pCMV-Tag2b-
FLAG-SQSTM1-DUBA (E396X) (kind gift of Dr. Lynne J. Hocking, University of
Aberdeen, UK)59 and the GFP-tagged FYVESARA domain (PtdIns3P probe) (kindly
provided by S. Corvera) expression vectors were used for transfection
experiments as described.24 Empty vectors were used as control.
Transfection and RNA interference. Cells were transfected with 50 nM
of CFTR (Invitrogen), SQSTM1, BECN1, hVps15, ATG14 (PRIMM, Milan, Italy),
hVPS34 (Sigma-Aldrich) siRNA (Supplementary Table SI) or scrambled
oligonucleotides by Lipo RnaiMax (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer’s instructions or transfected with pcDNA3-HA-Beclin1,
GFP-FYVESARA, pcDNA3-HA-DF508-CFTR, pCMV-Tag2bFLAG-SQSTM1wt or
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pCMV-Tag2bFLAG-SQSTM1-DUBA(E396X) expression vectors, with the help of
lipofectamine 2000 (Invitrogen), according to the manufacturer’s instructions.
Immunoblot analysis, immunoprecipitation and CFTR ubiquiti-
nation. The whole or membrane fraction proteins were obtained from treated
and untreated cells, harvested, lysed and the amounts of proteins were
determined by a Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA) to ensure
equal protein loading before western blot analysis. Fifty micrograms of cell lysate
were loaded in each lane. Immunoprecipitation and CFTR ubiquitination were
performed with proteins of membrane fraction incubated at 4 1C for 8–12 h with
CFTR antibody (clone CF3, Abcam, Cambridge, UK) followed by the addition of
Protein A/G-agarose beads. After washing, the immunoprecipitated proteins were
subjected to electrophoresis through 8% polyacrylamide gels, transferred to blotting
membranes and analyzed. CFTR ubiquitination level was measured by densitometry
and normalized to the CFTR level in the precipitate. Densitometric analysis was
performed with Image J software (NIH, Bethesda, MD, USA); all data points were
expressed as means±S.D. of triplicates of three independent experiments.
Cell-surface biotinylation assay and membrane fractionation.
Cell-surface proteins were biotinylated using sulfosuccinimidyl-6-(biotinamido)
hexanoate (sulfo-NHS-LC-Biotin, 1 mg/ml in PBS, pH 8.2; Pierce, Rockford, IL,
USA), as described.27,60 Cells were homogenized with a Potter-Elvehjem pestle
and centrifuged at 2300 g for 15 min at 4 1C. Supernatants that contains the
cytoplasmic and PM fractions were centrifuged 1 h at 16 000 g at 4 1C; the pellet
was the intact membrane and was solubilized in BUFFER A (20 mM Tris-HCl pH
7.4, 2 mM EDTA, 20 mM 2-ME, 1 PMSF, 1mg/ml inhibitor protease cocktail)
þ 1% Triton X-100 and centrifuged 1 h at 60 000 g in the ultracentrifuge. The
supernatants were collected as PM fraction. Equivalent amounts of protein
(500mg) were used for streptavidin-agarose pull-down (Pierce). Biotinylated
proteins of PM fraction were immunoblotted against CFTR (clone M3A7) or TfR
and E-cadherin or b–actin. For transferrin: cells were starved for 1 h at 37 1C in
serum-free HEPES-buffered DMEM and then incubated for 1 h at 4 1C in the
continuous presence of 5 mg/ml Tf-unconjugated (Invitrogen) HEPES-buffered
DMEM. The cell were incubated at 37 1C for 15 min in growth medium and then
processed for biotnylation assay. The densitometric analysis and percentage
remaining was performed by Image J software and each data point is expressed
as the mean±S.D. of triplicate of three independent experiments.
Differential fractionation and separation of endosomes. The
separation of EE and LE fractions was performed as described.61 Briefly, cells were
homogenized gently to limit damage to endosomes, and a post-nuclear supernatant
(PNS) was prepared by centrifugation for 10 min at 1000 g, and then the PNS was
centrifuged at 20 000 g for 20 min. The supernatant was collected, and the pellet
was resuspended with 1 homogenization buffer (250 mM sucrose, 1 mM
Na2EDTA, 10 mM HEPES). The PNS was adjusted to 40.6% sucrose, loaded at
the bottom of an SW60 tube and then overlaid sequentially with 16% sucrose in
D2O, 10% sucrose in D2O and finally with homogenization buffer. The gradient was
centrifuged for 60 min at 60 000 g using an SW60 rotor. EEs were then collected
at the 16%/10% interface and LEs at the top of the 10% cushion.
Soluble and insoluble fractions. Cells were lysed in buffer containg
50 mM Tris- HCl pH 7.5, 150 mM NaCl, 0.5% Nonidet P40, 5 mM EDTA, 1 mM
phenylmethylsulphonyl fluoride, 50 mM NaF, 10 mg/ml leupeptin and 10mg/ml
apoprotein supplemented with protease inhibitors (Sigma-Aldrich) in presence of
2% SDS and centrifuged at 16 000 g at 4 1C for 20 min. After centrifugation, the
soluble (supernatant) and insoluble (pellet) fraction were used in western blot
analysis with anti-Rab5 antibody. The pellet insoluble in Nonidet P40 was
dissolved five times in sample buffer, boiled at 95 1C for 5 min and resolved on a
10% polyacrylamide gel.24
Antibodies. The following primary antibodies were used for blot analysis:
Ubiquitin (P4D1), 1 : 1000, CHIP, 1 : 500, hVps15\p150 (Nterm), 1 : 300, UVRAG,
1 : 500, Santa Cruz Biotechnology (Santa Cruz Inc, Santa Cruz, CA, USA);
SQSTM1, 1 : 1000, hVps34, 1 : 500, ATG14L, 1 : 750, Flag 1:1500 (Sigma-
Aldrich); CFTR clone M3A7, 1 : 500, EEA-1, 1 : 1000, Lamp-1, 1 : 1000, CFTR
(CF3), 1 : 1000, Rab-5, 1 : 1000, Rab-7, 1 : 1000, BECN1, 1 : 1000, Abcam;
E-Cadherin, 1 : 1000 and b-actin, 1 : 1000, Cell Signaling Technology (Cell
Signaling Inc., Danvers, MA, USA); and TfR, 1 : 800, Invitrogen.
The following primary antibodies were used for microscopy techniques: mouse
monoclonal antibodies against CFTR (CF3), 1 : 200, Abcam; SQSTM1(D3), 1 : 100,
HDAC6 (D11), 1 : 100, UVRAG, 1 : 300, Santa Cruz Biotechnology; rabbit polyclonal
antibodies against EEA-1, 1 : 400, Rab5, 1 : 400, LAMP-1, 1 : 400, Abcam; hVps-34,
1 : 500, SQSTM1, 1 : 400, Sigma-Aldrich; Rab11(D4F5), 1 : 400, Cell Signaling;
CFTR(H-182), 1 : 100, EGFR (1005), 1 : 100, Santa Cruz Biotechnology. The
Alexa-Fluor-488, Alexa-Fluor-546 secondary antibodies were obtained from
Molecular Probes (Invitrogen).
Immunofluorescence and confocal imaging. The cells were fixed for
10 min with 4% paraformaldehyde (PFA, Sigma-Aldrich) in PBS, quenched with
50 mM NH4Cl and permeabilized for 30 min in blocking buffer (0.1% (w/v) saponin,
0.5% (w/v) BSA in PBS/Ca/Mg). The cells were incubated for 2 h with the primary
antibody, washed three times in PBS, incubated for 1 h with the secondary (Alexa-
labelled) antibody, washed three times in PBS and were finally taken on
Vectashield-mounted coverslips. The samples were examined under a Zeiss LSM
510 confocal laser-scanning microscope (Carl Zeiss MicroImaging, Thornwood,
NY, USA) equipped with  63 oil-immersion objective and image processing was
done with Adobe Photoshop C2 (Adobe Sysytem Inc., San Jose, CA, USA). To
perform quantitative image analysis, 10–15 randomly chosen fields that included
8–10 cells each were scanned, using the same setting parameters (i.e., pinhole,
laser power, offset gain and detector amplification) below pixel saturation. The
mean intensity per cell was determined using the histogram function in the Zeiss
LSM 510 Software (version 3.2), and all of the pixel values above background
levels were quantified. All of the experiments were repeated at least three times,
and representative images are shown. Quantification of number of FYVESARA
spots per cell was performed using the AnalySIS software (Soft Imaging Systems
GmbH, Muenster, Germany). To quantify the levels of co-localization, confocal
serial sections were acquired from 8–10 cells per experimental condition, exported
in TIFF format and processed as previously described.62
Tf uptake and recycling. For transferrin uptake, cells were starved for 1 h at
37 1C in serum-free HEPES-buffered DMEM and then incubated for 1 h at 4 1C in the
continuous presence of 5mg/ml Tf–Alexa-Fluor-488 (Molecular Probes) HEPES-
buffered DMEM. The uptake of Tf and its movement along the endocytic pathway
were followed by incubating the cells at 37 1C for 5, 10, 15, 30 and 60 min in growth
medium. The cells were then treated with a mixture of 0.5 M NaCl and 0.5% acetic
acid (this acid wash removes Tf that is non-specifically bound to the PM) for 30 s
before being fixed and processed for immunofluorescence.
For transferrin recycling, cells were starved for 1 h at 37 1C, HEPES-buffered
DMEM and then incubated for 20 min at 37 1C in the continuous presence of 5 mg/ml
Tf–Alexa-Fluor-488 in serum-free, HEPES-buffered DMEM. After extensive
washing with serum-free HEPES-buffered DMEM, the recycling of Tf was
followed by incubating the cells at 37 1C in the presence of 50mg/ml unlabelled
Tf for 40 and 60 min in growth medium. The cells were then treated with a mixture
of 0.5 M NaCl and 0.5% acetic acid for 30 s before being fixed and processed for
immunofluorescence.
EGFR internalization and degradation. For EFGR internalization, the
cells were serum starved for 12 h at 37 1C in serum-free HEPES-buffered DMEM
to allow the EGFR to accumulate on the cell surface and then incubated for 1 h at
4 1C in the continuous presence of 100 ng/ml EGF–Alexa-Fluor-488 in serum-free
HEPES-buffered DMEM. The uptake of EGF and its movement along the
endocytic pathway were followed by incubating the cells at 37 1C for 5, 10,15, 30
and 60 min in growth medium. The cells were then treated with a mixture of
0.5 M NaCl and 0.5% acetic acid (this acid wash removes EGF that is
non-specifically bound to the PM) for 30 s before being fixed and processed for
immunofluorescence.
For EFGR degradation, the cells were stimulated by addition of EGF. At
designated intervals after addition of EGF, cells were fixed, permeabilized and
localization of the receptor was determined by immunofluorescence analysis using
the antibody against total EGFR.
Fluorescence resonance energy transfer microscopy. Cells were
immunostained with Alexa 546-anti-TG2 (Molecular Probes/Invitrogen)/Cy5-anti-
SUMO-1 (Santa Cruz Biotechnology), as previously described.24
ROS detection. Cells were pulsed with 10mM 5-(and-6)-chloromethyl-2070-
dichlorodihydrofluorescein diacetate acetyl ester (Molecular Probes) and analyzed
with Wallac 1420 multilabel Counter (Perkin Elmer, Zaventem, Belgium), as
described.24
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Iodide efflux. The analysis of the iodide efflux was performed by a iodide-
sensitive fluorescent indicator, SPQ (Molecular Probes, Invitrogen), as previously
described.22,27,53,63 The rates were calculated using SigmaPlot Version 7.1 (Systat
Software Inc., London, UK) for each mean fluorescence trace generated from the
50 cells examined per population per coverslip, as described.27
Statistical analysis. Data are reported as arithmetic mean±S.D. Data
distribution was analyzed for normality and statistical analysis performed using
the one-way ANOVA. Significant differences are indicated in the figures. All data
were obtained from independent measurements. Data were analyzed using SPSS
13 software (SPSS, Milan, Italy). Statistical significance was defined as P-value
of o0.05.
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